Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient

Author(s):  Bramwell Bethany

Issue:  Jul/Aug 2011 - Volume 15, Number 4
View All Articles in Issue

Page(s):  316-319

Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 1
Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 2
Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 3
Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient Page 4

Download in electronic PDF format for $75

Abstract:  The incidence of primary phenylketonuria in the U.S. is approximately 1 in 15,000 births. It is most common in whites, occurring in approximately 1 in 10,000 newborns. Tetrahydrobiopterin deficiency represents 1.5% to 2% of phenylketonuria cases, affecting approximately 1 in 1 million newborns. Most children with tetrahydrobiopterin deficiency are normal at birth, but, as phenylalanine accumulates, the child slowly develops cognitive and motor signs and symptoms resulting in severe mental retardation. In addition to intellectual disability, if untreated, progressive problems with development, movement disorders, difficulty swallowing, seizures, behavioral problems, and an inability to control body temperature will develop. Diagnosis and treatment is essential as early in life as possible to prevent irreversible neurological damage. If appropriate treatment is initiated in the first days of life, all manifestations of the disease can be prevented and patients can reach adult age with good outcomes.

Related Keywords: Bethany Bramwell, BS Pharm, RPh, tetrahydrobiopterin deficiency, BH4, primary phenylketonuria, phenylalanine accumulation, newborn infant, neonate, genetic inborn errors of metabolism, PKU, neurologic disorders, cognitive deficits, metabolic disorder, nitric oxide, dopamine, serotonin, carbidopa, levodopa, 5-hydroxytryptophan, 5-HTP, folinic acid, saptropterin dihydrochloride, selegiline hydrochloride, neurotransmitters, formulations, leucovorin

Related Categories: FORMULATIONS, MENTAL HEALTH, NUTRITION AND NUTRICEUTICALS, PEDIATRICS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient
Bramwell Bethany
Jul/Aug 2011
Pg. 316-319

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Compounding for the Pediatric Patient
Allen Loyd V Jr
Mar/Apr 1997
Pg. 84-86

Pediatric Dermatitis
Remmert Renee
Nov/Dec 2002
Pg. 419-421

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2
Cutter Christopher B
Mar/Apr 2004
Pg. 96-99

Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1
Cutter Christopher B
Jan/Feb 2004
Pg. 16-21

Testosterone Deficiency in Men: New Treatments for Andropause
Biundo Bruce
, Shippen Eugene
Nov/Dec 2000
Pg. 429-431

Acidifying Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 1999
Pg. 309-310

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Managing Zinc Deficiency in an Office Setting
Norwood Charles
, Chaney Bill, Moore Robert W
Nov/Dec 2000
Pg. 440-441

Patient Interest in Pharmacist-Provided Menopause and Hormone Replacement Therapy Consultations
Branvold Andrea
, Barner Jamie C
Nov/Dec 2003
Pg. 490-494

Compliance to Treatment in Elderly Dysphagic Patients: Potential Benefits of Alternate Dosage Forms
Bramwell Bethany L
Nov/Dec 2009
Pg. 498-505

Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
Jan/Feb 2019
Pg. 23-31

Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
Mar/Apr 2019
Pg. 94-104

Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina
, García Mónica Cristina, Jiminez-Kairuz Alvaro
Jul/Aug 2019
Pg. 324-331

Trichloroacetic Acid 20%, Salicylic Acid 20%, Lactic Acid 10% in Flexible Collodion
Allen Loyd V Jr
Sep/Oct 2015
Pg. 410

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Extemporaneous Formulations in Pediatric Patients
Nahata Milap C
Jul/Aug 1999
Pg. 274-276

Return to Top